Anita Dushyanth
Stock Analyst at Berenberg
(2.74)
# 1,892
Out of 4,905 analysts
4
Total ratings
75%
Success rate
15.74%
Average return
Main Sectors:
Stocks Rated by Anita Dushyanth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Initiates: Buy | $20 | $15.27 | +30.98% | 1 | Apr 27, 2022 | |
| SERA Sera Prognostics | Initiates: Buy | $13 | $2.92 | +345.21% | 1 | Apr 27, 2022 | |
| BTAI BioXcel Therapeutics | Initiates: Buy | $1,200 | $1.91 | +62,727.23% | 1 | Apr 9, 2021 | |
| PCRX Pacira BioSciences | Initiates: Buy | $93 | $21.59 | +330.85% | 1 | Apr 9, 2021 |
UroGen Pharma
Apr 27, 2022
Initiates: Buy
Price Target: $20
Current: $15.27
Upside: +30.98%
Sera Prognostics
Apr 27, 2022
Initiates: Buy
Price Target: $13
Current: $2.92
Upside: +345.21%
BioXcel Therapeutics
Apr 9, 2021
Initiates: Buy
Price Target: $1,200
Current: $1.91
Upside: +62,727.23%
Pacira BioSciences
Apr 9, 2021
Initiates: Buy
Price Target: $93
Current: $21.59
Upside: +330.85%